News
PULM
1.750
+8.02%
0.130
Pulmatrix Q4 EPS $(0.57) Beats $(1.04) Estimate, Sales $2.20M Beat $1.77M Estimate
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $0.57 per share. The company reported quarterly sales of $2.20 million. Pulmatrix beat the analyst consensus estimate of $1.77 million by 24.41 percent.
Benzinga · 1d ago
Pulmatrix GAAP EPS of -$3.87, revenue of $7.3M
Seeking Alpha · 1d ago
Press Release: Pulmatrix Announces Year-End and -2-
Pulmatrix is a clinical-stage biopharmaceutical company focused on the development of novel inhaled therapeutic products. Pulmatrix's product pipeline includes treatments for central nervous system disorders and serious lung diseases. The company's net loss for the quarter was $18,836.
Dow Jones · 1d ago
Press Release: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
Pulmatrix Announces Year-End and Q4 2023 financial results and Provides Corporate Update. $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026. Pulmatrix is a clinical-stage company developing inhaled therapies to address serious central nervous system and pulmonary disease. The company has wind down of the PUR1900 Phase 2b study.
Dow Jones · 1d ago
Weekly Report: what happened at PULM last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at PULM last week (0311-0315)?
Weekly Report · 03/18 09:46
Pulmatrix Shifts to Outsourced CMO Model, Terminates Executive
Pulmatrix terminated its Chief Medical Officer, Dr. Margaret Wasilewski, as part of a move to an outsourced, part-time CMO model. The decision was not due to any disagreements on company operations or practices. PULM will receive severance benefits.
TipRanks · 03/13 10:12
Weekly Report: what happened at PULM last week (0304-0308)?
Weekly Report · 03/11 09:45
Pulmatrix to Present at Investor Conferences, Limits Updates
TipRanks · 03/04 21:24
Weekly Report: what happened at PULM last week (0226-0301)?
Weekly Report · 03/04 09:46
Weekly Report: what happened at PULM last week (0219-0223)?
Weekly Report · 02/26 09:50
Weekly Report: what happened at PULM last week (0212-0216)?
Weekly Report · 02/19 09:50
Weekly Report: what happened at PULM last week (0205-0209)?
Weekly Report · 02/12 09:46
Weekly Report: what happened at PULM last week (0129-0202)?
Weekly Report · 02/05 09:50
Weekly Report: what happened at PULM last week (0122-0126)?
Weekly Report · 01/29 09:46
Weekly Report: what happened at PULM last week (0115-0119)?
Weekly Report · 01/22 09:48
Weekly Report: what happened at PULM last week (0108-0112)?
Weekly Report · 01/15 09:46
Pulmatrix: Current report
Press release · 01/08 16:00
Pulmatrix To Stop PUR1900 Phase 2B Study Patient Enrollment And Closing The Study
NASDAQ · 01/08 14:50
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives
Pulmatrix will close a study of a potential treatment for a fungal lung infection. The biopharmaceutical company says it will pursue strategic alternatives. Cipla, its partner in developing the treatment, will take responsibility for the development of the treatment. The company said it will focus on limiting cash burn and pursuing alternatives.
Dow Jones · 01/08 14:23
More
Webull provides a variety of real-time PULM stock news. You can receive the latest news about Pulmatrix through multiple platforms. This information may help you make smarter investment decisions.
About PULM
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing inhaled therapies to address serious pulmonary diseases and central nervous system (CNS) disorders using its patented inhaled small particles easily respirable and emitted (iSPERSE) technology. Its inhaled therapeutic products based on its dry powder delivery technology, namely iSPERSE enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. Its iSPERSE’s lead development program, PUR1900 is its inhaled formulation of itraconazole, an anti-fungal drug commercially available as an oral drug, which it is developing to treat and prevent pulmonary fungal infections. Its pipeline also includes PUR3100 for the treatment of acute migraine, and PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).